These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 37435073)

  • 1. Unraveling the interplay between norovirus infection, gut microbiota, and novel antiviral approaches: a comprehensive review.
    Bai GH; Tsai MC; Lin SC; Hsu YH; Chen SY
    Front Microbiol; 2023; 14():1212582. PubMed ID: 37485533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends on Human Norovirus Virus-like Particles (HuNoV-VLPs) and Strategies for the Construction of Infectious Viral Clones toward In Vitro Replication.
    Sion E; Ab-Rahim S; Muhamad M
    Life (Basel); 2023 Jun; 13(7):. PubMed ID: 37511822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fucose Binding Cancels out Mechanical Differences between Distinct Human Noroviruses.
    Feng Y; Pogan R; Thiede L; Müller-Guhl J; Uetrecht C; Roos WH
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significantly Longer Shedding of Norovirus Compared to Rotavirus and Adenovirus in Children with Acute Gastroenteritis.
    Qiu Y; Freedman SB; Williamson-Urquhart S; Farion KJ; Gouin S; Poonai N; Schuh S; Finkelstein Y; Xie J; Lee BE; Chui L; Pang X; On Behalf Of The Pediatric Emergency Research Canada Probiotic Regimen For Outpatient Gastroenteritis Utility Of Treatment Progut Trial Group
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gut protist Tritrichomonas arnold restrains virus-mediated loss of oral tolerance by modulating dietary antigen-presenting dendritic cells.
    Medina Sanchez L; Siller M; Zeng Y; Brigleb PH; Sangani KA; Soto AS; Engl C; Laughlin CR; Rana M; Van Der Kraak L; Pandey SP; Bender MJ; Fitzgerald B; Hedden L; Fiske K; Taylor GM; Wright AP; Mehta ID; Rahman SA; Galipeau HJ; Mullett SJ; Gelhaus SL; Watkins SC; Bercik P; Nice TJ; Jabri B; Meisel M; Das J; Dermody TS; Verdú EF; Hinterleitner R
    Immunity; 2023 Aug; 56(8):1862-1875.e9. PubMed ID: 37478853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and evaluation of a new luciferase immunosorbent assay to detect GII.6 norovirus-specific IgG in different domestic and wild animals.
    Liang Z; Zhang M; Wang Y; Koroma MM; Yu J; Zhou F; Jing D; Li J; Tang S; Chen Q; Dai YC
    Front Microbiol; 2023; 14():1213007. PubMed ID: 37547694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Chimeric Hepatitis B (HBV) - Norovirus (NoV) P particle as candidate vaccine against Hepatitis B and norovirus infection.
    Giri-Rachman EA; Irasonia Tan M; Ramesh A; Fajar PA; Nurul Ilmi A; Retnoningrum DS; Hertadi R; Irawan A; Wojciechowska GEP; Yuan L
    Vaccine X; 2023 Aug; 14():100354. PubMed ID: 37519778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Evolutionary Analyses of the RNA-Dependent RNA Polymerase (
    Takahashi T; Kimura R; Shirai T; Sada M; Sugai T; Murakami K; Harada K; Ito K; Matsushima Y; Mizukoshi F; Okayama K; Hayashi Y; Kondo M; Kageyama T; Suzuki Y; Ishii H; Ryo A; Katayama K; Fujita K; Kimura H
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenetic characteristics of infectious diarrhea in Yantai City, Shandong Province, 2018-2019.
    Gao Q; Liu H; Yu W; Wang Z; Yang Y; Guo K; Sun Z
    Front Public Health; 2023; 11():1195118. PubMed ID: 37483931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norovirus-associated neurological manifestations: summarizing the evidence.
    Deb S; Mondal R; Lahiri D; Shome G; Roy AG; Sarkar V; Sarkar S; Benito-León J
    J Neurovirol; 2023 Aug; 29(4):492-506. PubMed ID: 37477790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predominance of recombinant Norovirus GII.4Sydney[P16] strains in children less than 5 years of age with acute gastroenteritis in Tehran, Iran, 2021-2022.
    Eftekhari M; Kachooei A; Jalilvand S; Latifi T; Habib Z; Ataei-Pirkoohi A; Marashi SM; Shoja Z
    Virus Res; 2023 Sep; 334():199172. PubMed ID: 37459917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approach to patient reported outcome measures selection and implementation in a chronic norovirus clinical efficacy trial for patients after solid organ transplant.
    Keefer L; Daud A; Ison M;
    Transpl Infect Dis; 2023 Aug; 25(4):e14099. PubMed ID: 37436814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis.
    Kapikian AZ; Wyatt RG; Dolin R; Thornhill TS; Kalica AR; Chanock RM
    J Virol; 1972 Nov; 10(5):1075-81. PubMed ID: 4117963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine Strategies to Elicit Mucosal Immunity.
    Song Y; Mehl F; Zeichner SL
    Vaccines (Basel); 2024 Feb; 12(2):. PubMed ID: 38400174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant.
    Waerlop G; Janssens Y; Jacobs B; Jarczowski F; Diessner A; Leroux-Roels G; Klimyuk V; Leroux-Roels I; Thieme F
    Front Immunol; 2023; 14():1188431. PubMed ID: 37435073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.
    Leroux-Roels I; Maes C; Joye J; Jacobs B; Jarczowski F; Diessner A; Janssens Y; Waerlop G; Tamminen K; Heinimäki S; Blazevic V; Leroux-Roels G; Klimyuk V; Adachi H; Hiruta K; Thieme F
    Front Immunol; 2022; 13():1021500. PubMed ID: 36275772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.
    Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ
    Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.
    Parra GI; Bok K; Taylor R; Haynes JR; Sosnovtsev SV; Richardson C; Green KY
    Vaccine; 2012 May; 30(24):3580-6. PubMed ID: 22469864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological Correlates of Protection against a GII.4 Norovirus.
    Atmar RL; Bernstein DI; Lyon GM; Treanor JJ; Al-Ibrahim MS; Graham DY; Vinjé J; Jiang X; Gregoricus N; Frenck RW; Moe CL; Chen WH; Ferreira J; Barrett J; Opekun AR; Estes MK; Borkowski A; Baehner F; Goodwin R; Edmonds A; Mendelman PM
    Clin Vaccine Immunol; 2015 Aug; 22(8):923-9. PubMed ID: 26041041
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.